Alto Partners backs Diatech

Following the deal, CEO Oliva Alberti and chair Fabio Biondi will stay on with the business and maintain their current roles.

Banca Popolare di Sondrio provided a debt package to support the deal.

The GP invested in the company via Alto Capital IV, which held a final close on its €210m hard-cap in April 2018. The vehicle targets Italian SMEs generating revenues within the €20-80m bracket, and deploys equity tickets of €15-25m.

With Alto's support, Diatech plans to expand across the international markets, build new partnerships with pharmaceutical companies, and further widen its range of products for oncology diagnostics.

Company
Founded in 1998 and headquartered in Jesi, Diatech is a producer of reagents and customised genomic testing for molecular diagnostics and pharmacogenetics used in oncology.

Employing 60 staff, the company generated EBITDA of around €12m from revenues of €32.5m in 2020.

People
Alto Partners – Enrico Ricotta (partner).
Diatech – Oliva Alberti (CEO); Fabio Biondi (chair).

Advisers
Alto Partners – LMCR (legal); PMSI (commercial due diligence); Athena Audit (financial due diligence); Tauw (ESG due diligence); Sopabroker (insurance due diligence).
Company – Cross Border (corporate finance); Pedersoli Studio Legale (legal).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• Southern Europe
• Healthcare
• Alto Partners
• Italy